Drug intelligence / Profile preview

glauconite

Development stage: Preclinical

Overview

Glauconite is a biologically active mineral that, in its activated form (fatifiltrum), is being investigated for its medicinal properties in the treatment of atopic dermatitis. It functions as a detoxifying agent, aiming to reduce endogenous intoxication in patients. Clinical studies have shown that activated glauconite contributes to a significant decrease in the SCORAD index and the degree of endogenous intoxication, suggesting its potential for widespread use in dermatological practice.

Other names: fatifiltrumactivated glauconite

Targets

IS (Indoxyl sulfate)

Beyond the preview

Go deeper on glauconite.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glauconite.

Explore the full profile